Jennifer B. Marks

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

Mark D. Pescovitz, Carla J. Greenbaum, Heidi Krause‐Steinrauf et al. · New England Journal of Medicine · 2009 · 1.1K citations · Full text

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

Kevan C. Herold, Brian N. Bundy, S. Alice Long et al. · New England Journal of Medicine · 2019 · 1K citations · Full text

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

Tihamer Orban, Brian N. Bundy, Dorothy J. Becker et al. · The Lancet · 2011 · 589 citations

Diabetes Management, Diabetes, Co-stimulation Modulation +7

Validation of the insulin sensitivity index (ISI0,120): comparison with other measures

M. Gutt, Catherine L. Davis, Susan B. Spitzer et al. · Diabetes Research and Clinical Practice · 2000 · 471 citations

Obesity, Metabolic Syndrome, Diabetes Management +11